| 2026 | Impact of metabolic dysfunction-associated steatotic liver disease on liver metastasis and survival in pancreatic cancer
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2026 | Diagnostic Value of MR Elastography and MRI-Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology
| JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2026 | Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2026 | A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2026 | Fibrotic MASH resolutionVCTE index to diagnose fibrotic MASH resolution and predict LREs: A global multicenter study | MED(Med (New York, N.Y.)) |
| 2026 | Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2026 | Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD | JOURNAL OF HEPATOLOGY |
| 2026 | Integration of PNPLA3 and TM6SF2 genotypes provides incremental improvement in advanced fibrosis prediction among MASLD patients with type 2 diabetes mellitus
| JHEP REPORTS |
| 2026 | Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery
| JOURNAL OF INFECTION AND PUBLIC HEALTH |
| 2026 | Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes | GUT |
| 2026 | Correspondence to editorial on "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2026 | Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis | DIAGNOSTIC AND INTERVENTIONAL IMAGING |
| 2026 | Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2025 | Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD | HEPATOLOGY |
| 2025 | Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease | HEPATOLOGY |
| 2025 | The Impact of Liraglutide on Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study | HEPATOLOGY |
| 2025 | Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model
| BMC CANCER |
| 2025 | Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis
| JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | Sarcopenia and MASLD: novel insights and the future | NATURE REVIEWS ENDOCRINOLOGY |
| 2025 | Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study | HEPATOLOGY |
| 2025 | Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study | AMERICAN JOURNAL OF GASTROENTEROLOGY |
| 2025 | Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990-2021 | AMERICAN JOURNAL OF GASTROENTEROLOGY |
| 2025 | Association between longitudinal weight change and clinical outcome in individuals with MASLD | HEPATOLOGY |
| 2025 | From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective | GASTROENTEROLOGY |
| 2025 | Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
| SCIENTIFIC REPORTS |
| 2025 | Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease | JOURNAL OF HEPATOLOGY |
| 2025 | Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy-Induced HBsAg Seroclearance | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2025 | Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease | GUT |
| 2025 | Reply to: "Unlock AI-Safe-C score's potential at all levels: Improve methods and overcome barriers" | JOURNAL OF HEPATOLOGY |
| 2025 | AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | JOURNAL OF HEPATOLOGY |
| 2025 | Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance: A Randomized, Single-Center Trial | GASTROENTEROLOGY |
| 2025 | Repurposing of Antiplatelet Agent: Cilostazol for the Treatment of Alcohol-Related Liver Disease
| GUT AND LIVER |
| 2025 | Global Burden of Major Chronic Liver Diseases in 2021 | LIVER INTERNATIONAL |
| 2025 | The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease | HEPATOLOGY INTERNATIONAL |
| 2025 | Correspondence to editorial on "Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C"
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2025 | Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy A multicenter study for chronic hepatitis C
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2025 | acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2025 | AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment | JOURNAL OF HEPATOLOGY |
| 2025 | Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
| JHEP REPORTS |
| 2025 | Identification of new biomarkers of hepatic cancer stem cells through proteomic profiling | Journal of Liver Cancer(대한간암학회지) |
| 2025 | Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma
| CANCERS |
| 2025 | A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B | JOURNAL OF HEPATOLOGY |
| 2025 | Correspondence to editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis"
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2025 | Correspondence to editorial on "Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis"
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2025 | Correspondence to editorial on "Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2025 | Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study
| JHEP REPORTS |
| 2025 | Is liver resection still required for patients who have predictive factors for complete pathologic necrosis after downstaging treatments of locally advanced hepatocellular carcinoma? | EJSO |
| 2024 | Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
http://orcid.org/0000-0002-9658-8050
(54933821200)
